Ritonavir

Drugs

Volumn 52, Issue 4, 1996, Pages 541-546

  Lea, A P ^a   Faulds, D ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIVIRUS AGENT; CD4 ANTIGEN; INDINAVIR; LAMIVUDINE; NELFINAVIR; RITONAVIR; SAQUINAVIR; UNINDEXED DRUG; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; BLEEDING; CLINICAL TRIAL; DRUG BIOAVAILABILITY; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MORTALITY; NEUROTOXICITY; REVIEW; RISK; VIREMIA;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0029840569     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199652040-00007     Document Type: Review

References (37)

1. 1. G. Moyle B. Gazzard 1996 Current knowledge and future prospects for the use of HIV protease inhibitors Drugs 51 5 701 12 8861542 10.2165/00003495-199651050-00001 1:CAS:528:DyaK28XjsVehsbg%3D Moyle G, Gazzard B. Current knowledge and future prospects for the use of HIV protease inhibitors. Drugs 1996 May; 51(5): 701–12
2. 2. D.J. Kempf K.C. Marsh J.F. Denissen 1995 ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans Proc Natl Acad Sci USA 92 2484 8 7708670 10.1073/pnas.92.7.2484 1:CAS:528:DyaK2MXksl2kur8%3D Kempf DJ, Marsh KC, Denissen JF, et al. ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans. Proc Natl Acad Sci USA 1995 Mar 28; 92: 2484–8
3. 3. D.D. Ho A.U. Neumann A.S. Perelson 1995 Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection [see comments] Nature 373 123 6 7816094 10.1038/373123a0 1:CAS:528:DyaK2MXjtFSrt7o%3D Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection [see comments]. Nature 1995 Jan 12; 373: 123–6
4. 4. A.D. Kelleher A. Carr J. Zaunders 1996 Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir J Infect Dis 173 321 9 8568292 10.1093/infdis/173.2.321 1:CAS:528:DyaK28Xhtlyru7g%3D Kelleher AD, Carr A, Zaunders J. Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996 Feb; 173: 321–9
5. 5. A. Molla M. Korneyeva Q. Gao 1996 Ordered accumulation of mutations in HIV protease confers resistance to ritonavir Natur Med 2 7 760 6 10.1038/nm0796-760 1:CAS:528:DyaK28XjvF2isr4%3D Molla A, Korneyeva M, Gao Q, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Natur Med 1996; 2(7): 760–6
6. 6. S.P. Eastman K. Reed E. Boyer 1996 Loss of suppression of viral replication by ritonavir (ABT-538) is quantitatively associated with the acquisation of genotypic mutations at codon 82 of the HIV-1 protease gene [abstract] Third Conference on Retroviruses and Opportunistic Infections Washington DC 90 Eastman SP, Reed K, Boyer E, et al. Loss of suppression of viral replication by ritonavir (ABT-538) is quantitatively associated with the acquisation of genotypic mutations at codon 82 of the HIV-1 protease gene [abstract]. Third Conference on Retroviruses and Opportunistic Infections: 1996 Jan 28; Washington DC, 90
7. 7. M. Markowitz H. Mo D.J. Kempf 1995 Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor J Virol 69 701 6 7815532 1:CAS:528:DyaK2MXjtlGqsrg%3D Markowitz M, Mo H, Kempf DJ, et al. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol 1995 Feb; 69: 701–6
8. 8. J.H. Condra W.A. Schlief O.M. Blahy 1995 In vivo emergence of HIV-1 variants resistant to multiple protease inhibiters [letter] Nature 374 569 71 7700387 10.1038/374569a0 1:CAS:528:DyaK2MXkvVKqtrY%3D Condra JH, Schlief WA, Blahy OM, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibiters [letter]. Nature 1995 Apr 6; 374: 569–71
9. 9. A. Hsu R. Granneman K. Rynkiewicz 1994 Kinetics of ABT-538, a protease inhibitor, in humans after single oral rising doses [abstract] Pharm Res 11 400 Hsu A, Granneman R, Rynkiewicz K, et al. Kinetics of ABT-538, a protease inhibitor, in humans after single oral rising doses [abstract]. Pharm Res 1994 Oct; 11 Suppl.: 400
10. 10. S.A. Danner A. Carr J.M. Leonard 1995 A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease N Engl J Med 333 1528 33 7477167 10.1056/NEJM199512073332303 1:CAS:528:DyaK28XnvFKqsQ%3D%3D Danner SA, Carr A, Leonard JM. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995 Dec 7; 333: 1528–33
11. 11. Norvir™ (ritonavir capsules) (ritonavir oral solution). Prescribing Information. Abbott Laboratories, Chicago, Illinois, USA
12. 12. Data on file. Abbott Laboratories, Chicago, Illinois, USA. 1996
13. 13. G.N. Kumar D. Rodrigues A.M. Buko 1996 Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes J Pharmacol Exp Ther 277 1 423 31 8613951 1:CAS:528:DyaK28XitlCmtbc%3D Kumar GN, Rodrigues D, Buko AM, et al. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996; 277(1): 423–31
14. 14. D. Quellet A. Hsu J. Qian 1996 Effect of ritonavir on the pharmacokinetics of ethinyl estradiol in healthy female volunteers [abstract] XI International Conference on AIDS Vancouver Quellet D, Hsu A, Qian J, et al. Effect of ritonavir on the pharmacokinetics of ethinyl estradiol in healthy female volunteers [abstract]. XI International Conference on AIDS; 1996 Jul 7; Vancouver
15. 15. A. Hsu G.R. Granneman G. Witt 1996 Assessment of multiple doses of ritonavir on the pharmacokinetics of theophylline [abstract] XI International Conference on AIDS Vancouver Hsu A, Granneman GR, Witt G, et al. Assessment of multiple doses of ritonavir on the pharmacokinetics of theophylline [abstract]. XI International Conference on AIDS: 1996 Jul 7; Vancouver
16. 16. G.N. Kumar B. Grabowski R. Lee 1996 Hepatic drug-metabolizing activities in rats after 14 days of oral administration of the human immunodeficiency virus-type 1 protease inhibitor ritonavir (ABT-538) Drug Metab Dispos 24 5 615 7 8723745 1:CAS:528:DyaK28XivVOmsrw%3D Kumar GN, Grabowski B, Lee R, et al. Hepatic drug-metabolizing activities in rats after 14 days of oral administration of the human immunodeficiency virus-type 1 protease inhibitor ritonavir (ABT-538). Drug Metab Dispos 1996; 24(5): 615–7
17. 17. A. Cato J.H. Cavanaugh A. Shi 1996 Assessment of multiple doses of ritonavir on the pharmacokinetics of rifabutin [abstract] XI International Conference on AIDS Vancouver 89 Cato A, Cavanaugh JH, Shi A, et al. Assessment of multiple doses of ritonavir on the pharmacokinetics of rifabutin [abstract]. XI International Conference on AIDS: 1996 Jul 7; Vancouver, 89
18. 18. D. Altarac B.S. Koll 1996 Management of the patient with human immunodeficiency virus disease R.E. Rakel Conn’s Current Therapy 48 WB Saunders Company Philadelphia 47 66 Altarac D, Koll BS. Management of the patient with human immunodeficiency virus disease. In: Rakel RE, editor. Conn’s Current Therapy. 48th ed. Philadelphia: WB Saunders Company, 1996: 47–66
19. 19. D. Oullet A. Hsu G.R. Granneman 1996 Assessment of the pharmacokinetic interaction between ritonavir (R) and clarithromycin (C) Clin Pharmacol Ther 59 2 143 10.1038/sj.clpt.1996.73 Oullet D, Hsu A, Granneman GR, et al. Assessment of the pharmacokinetic interaction between ritonavir (R) and clarithromycin (C). Clin Pharmacol Ther 1996; 59(2): 143
20. 20. D. Kempf K. Marsh J. Denissen 1996 Coadministration with ritonavir enhances the plasma levels of HIV protease inhibitors by inhibition of cytochrome P450 [abstract] Third Conference on Retroviruses and Opportunistic Infections Washington DC 79 Kempf D, Marsh K, Denissen J, et al. Coadministration with ritonavir enhances the plasma levels of HIV protease inhibitors by inhibition of cytochrome P450 [abstract]. Third Conference on Retroviruses and Opportunistic Infections: 1996 Jan 28; Washington DC, 79
21. 21. A. Hsu G.R. Granneman E. Sun 1996 Assessment of single-and multiple-dose interactions between ritonavir and saquinavir [abstract] XI International Conference on AIDS Vancouver Hsu A, Granneman GR, Sun E, el al. Assessment of single-and multiple-dose interactions between ritonavir and saquinavir [abstract]. XI International Conference on AIDS: 1996 Jul 7; Vancouver
22. 22. A. Cato J. Qian L. Carothers 1996 Evaluation of the pharmacokinetic interaction between ritonavir and didanosine [abstract] Clin Pharmacol Ther 59 2 144 10.1038/sj.clpt.1996.74 Cato A, Qian J, Carothers L, et al. Evaluation of the pharmacokinetic interaction between ritonavir and didanosine [abstract]. Clin Pharmacol Ther 1996; 59(2): 144
23. 23. A. Cato A. Hsu R. Granneman 1995 Assessment of the pharmacokinetic interaction between the HIV-1 protease inhibitor ABT-538 and fluconazole [abstract] 35th International Conference on Antimicrobial Agents and Chemotherapy 211 Cato A, Hsu A, Granneman R, et al. Assessment of the pharmacokinetic interaction between the HIV-1 protease inhibitor ABT-538 and fluconazole [abstract]. 35th International Conference on Antimicrobial Agents and Chemotherapy: 1995 Sep 17; 211
24. 24. A. Cato A. Hsu R. Granneman 1995 Assessment of the pharmacokinetic interaction between the HIV-1 protease inhibitor ABT-538 and zidovudine [abstract] 35th International Conference on Antimicrobial Agents and Chemotherapy 211 Cato A, Hsu A, Granneman R, et al. Assessment of the pharmacokinetic interaction between the HIV-1 protease inhibitor ABT-538 and zidovudine [abstract]. 35th International Conference on Antimicrobial Agents and Chemotherapy; 1995 Sep 17; 211
25. 25. M. Markowitz M. Saag W.G. Powderly 1995 A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection N Engl J Med 333 1534 9 7477168 1:CAS:528:DyaK28XnvFKqtg%3D%3D Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995 Dec 7; 333: 1534–9
26. 26. B.U. Mueller J. Zuckerman R.P. Nelson Jr. 1996 A phase I/II study of the protease inhibitor ritonavir (ABT-538) in children with HIV infection [abstract] XI International Conference on AIDS 2 Vancouver 31 Mueller BU, Zuckerman J, Nelson Jr. RP, et al. A phase I/II study of the protease inhibitor ritonavir (ABT-538) in children with HIV infection [abstract]. XI International Conference on AIDS 2: 1996 Jul 7; Vancouver, 31
27. 27. B. Cameron M. Heath-Chiozzi S. Kravcik 1996 Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir [abstract] Third Conference on Retroviruses and Opportunistic Infections Washington DC 162 Cameron B, Heath-Chiozzi M, Kravcik S, et al. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir [abstract]. Third Conference on Retroviruses and Opportunistic Infections: 1996 Jan 28; Washington DC, 162
28. 28. D.W. Cameron M. Heath-Chiozzi S. Kravcik 1996 Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with ritonavir: update [abstract] XI International Conference on AIDS Vancouver Cameron DW, Heath-Chiozzi M, Kravcik S, et al. Prolongation of life and prevention of AIDS complications in advanced HIV immunodeficiency with ritonavir: update [abstract]. XI International Conference on AIDS: 1996 Jul 7; Vancouver
29. 29. M. Heath-Chiozzi J. Leonard D. Henry 1996 Anti-HIV activity and lymphocyte surrogate marker response dynamics to ritonavir therapy in advanced HIV immunodeficiency [abstract] Third Conference on Retroviruses and Opportunistic Infections Washington DC Heath-Chiozzi M, Leonard J, Henry D, et al. Anti-HIV activity and lymphocyte surrogate marker response dynamics to ritonavir therapy in advanced HIV immunodeficiency [abstract]. Third Conference on Retroviruses and Opportunistic Infections; 1996 Jan 28; Washington DC.
30. 30. A. Nabulsi D. Revicki D. Conway 1996 The use of EuroQol preference scale in AIDS. Results from two clinical trials [abstract] XI International Conference on AIDS Vancouver Nabulsi A, Revicki D, Conway D, et al. The use of EuroQol preference scale in AIDS. Results from two clinical trials [abstract]. XI International Conference on AIDS: 1996 Jul 7; Vancouver
31. 31. Abbott Novir for HIV reduces death risk 40%, reduces disease progression risk 55% in advanced HIV; FDA approves ritonavir March 1 in record 72 days. FDC Rep Pink Sheet 1996 Mar 4: 7-8
32. 32. US NDA for Abbott’s ritonavir. Scrip 1996Jan 2/5; 2090/91: 23
33. 33. Swift US approval for Abbott’s Norvir. Scrip 1996 Mar 8; 2109: 17
34. 34. D. Mathez P. Truchis De I. Gorin 1996 A triple combination of ritonavir+AZT+DDC as a first line treatment of patients with AIDS: update [poster] XI International Conference on AIDS Vancouver Mathez D, De Truchis P, Gorin I, et al. A triple combination of ritonavir+AZT+DDC as a first line treatment of patients with AIDS: update [poster]. XI International Conference on AIDS: 1996 Jul 7; Vancouver
35. 35. M. Markowitz Y. Cao A. Hurley 1996 Triple therapy with AZT, 3TC, and ritonavir in 12 subjects newly infected with HIV-1 [abstract] XI International Conference on AIDS Vancouver Markowitz M, Cao Y, Hurley A, et al. Triple therapy with AZT, 3TC, and ritonavir in 12 subjects newly infected with HIV-1 [abstract]. XI International Conference on AIDS: 1996 Jul 7; Vancouver
36. 36. W. Cameron E. Sun M. Markowitz 1996 Combination use of ritonavir and saquinavir in HIV-infected patients: preliminary safety and activity data [abstract] XI International Conference on AIDS Vancouver Cameron W, Sun E, Markowitz M, et al. Combination use of ritonavir and saquinavir in HIV-infected patients: preliminary safety and activity data [abstract]. XI International Conference on AIDS: 1996 Jul 7; Vancouver
37. 37. FDA. HIV protease inhibitors and patients with hemophilia. Letter to Healthcare Providers. FDA: 1996 Jul 17